维纳卡兰与普鲁卡因胺用于急性心房颤动快速复律的比较(RAFF4):随机临床试验
RAFF4随机临床试验在加拿大12家三级急诊科比较静脉维纳卡兰与普鲁卡因胺对急性心房颤动的复律效果与安全性。维纳卡兰组30分钟内复律成功率62.4%高于普鲁卡因胺组48.3%(校正绝对差15.0%,95%CI 4.6%至25.0%,P=0.005),复律时间更快(21.8 vs 44.7分钟),且更少患者需尝试电复律。
要点
- 维纳卡兰30分钟内复律成功率62.4%,高于普鲁卡因胺的48.3%(P=0.005)。
- 维纳卡兰复律时间21.8分钟,快于普鲁卡因胺的44.7分钟(P<0.001)。
- 维纳卡兰组尝试电复律比例33.7%,低于普鲁卡因胺组的44.2%(P=0.033)。
核心结论
- 在头对头比较中,维纳卡兰复律成功率更高、复律时间更快,优于普鲁卡因胺。
- 维纳卡兰是急性心房颤动患者快速复律并离院回家的安全且高效的静脉替代选择。
研究设计与样本
- 随机、开放标签临床试验(RAFF4试验),在加拿大12家三级急诊科开展。
- 共纳入350例适合急性心律控制的急性心房颤动患者,按1:1随机接受静脉维纳卡兰或普鲁卡因胺输注;未快速转复者接受电复律。
- 普鲁卡因胺组172例,维纳卡兰组178例,两组基线特征相似。
主要发现
- 主要结局复律成功:维纳卡兰组62.4% vs 普鲁卡因胺组48.3%(校正绝对差15.0%,95%CI 4.6%至25.0%,P=0.005;校正OR 1.87,95%CI 1.2至2.9,P=0.006)。
- 复律时间:维纳卡兰组21.8分钟 vs 普鲁卡因胺组44.7分钟(平均差-22.9,95%CI -29.9至-16.0,P<0.001)。
- 尝试电复律比例:维纳卡兰组33.7% vs 普鲁卡因胺组44.2%(OR 0.62,95%CI 0.39至0.96,P=0.033)。
- 不良反应两组相似,总体轻微且短暂,多数患者离院回家。
- 亚组分析:年龄小于70岁患者中维纳卡兰复律优势明显(73.3% vs 47.2%;校正OR 3.1,95%CI 1.7至5.5,P=0.001,交互作用P=0.005)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To conduct a randomised, open label comparison of the effectiveness and safety of intravenous vernakalant and intravenous procainamide for the management of acute atrial fibrillation in the emergency department. DESIGN: Randomised clinical trial (RAFF4 trial). SETTING: 12 tertiary care emergency departments in Canada. PARTICIPANTS: Patients with acute atrial fibrillation for whom acute rhythm control was a safe option. INTERVENTIONS: Patients were randomised (1:1) to an intravenous infusion of vernakalant or procainamide; when rapid conversion did not occur, patients were offered electrical cardioversion. MAIN OUTCOMES AND MEASURES: The primary outcome was conversion to sinus rhythm within 30 minutes of drug infusion completion. Secondary outcomes included time to conversion to sinus rhythm and whether the patient required electrical cardioversion. RESULTS: Of the 350 enrolled eligible patients, baseline characteristics were similar in the procainamide (n=172) and vernakalant (n=178) groups. For the primary outcome of conversion success, vernakalant was more effective (62.4% v 48.3%; adjusted absolute difference 15.0%, 95% confidence interval 4.6% to 25.0%, P=0.005; adjusted odds ratio 1.87, 95% confidence interval 1.2 to 2.9, P=0.006). With vernakalant, time to conversion was faster (21.8 v 44.7 minutes; mean difference -22.9, 95% confidence interval -29.9 to -16.0, P<0.001), and fewer patients underwent attempted electrical cardioversion (33.7% v 44.2%; odds ratio 0.62, 95% confidence interval 0.39 to 0.96, P=0.033). Adverse events were similar in both groups, were generally mild and brief, and most patients were discharged home. Subgroup analysis strongly favoured vernakalant for conversion in patients younger than 70 years (73.3% v 47.2%; adjusted odds ratio 3.1, 95% confidence interval 1.7 to 5.5, P=0.001, interaction P=0.005). CONCLUSIONS: In this head-to-head comparison, vernakalant was superior to procainamide for patients with higher conversion rates and faster times to conversion. Therefore, vernakalant is a safe and highly effective intravenous alternative for the rapid cardioversion and discharge home of patients with acute atrial fibrillation. TRIAL REGISTRATION: ClinicalTrials.gov NCT04485195.
引用
- Stiell IG, Taljaard M, Eagles D, et al. Vernakalant versus procainamide for rapid cardioversion of patients with acute atrial fibrillation (RAFF4): randomised clinical trial. BMJ. 2025. PMID: 41218981. doi:10.1136/bmj-2025-085632
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。